PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1997 April; 90(4): 200–204.
PMCID: PMC1296215

Leukotriene receptor antagonists: clinical effects.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (934K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Piper PJ. Leukotrienes and the airways. Eur J Anaesthesiol. 1989 Jul;6(4):241–255. [PubMed]
  • Barnes NC, Kuitert L. Influence of leukotriene antagonists on baseline pulmonary function and asthmatic responses. Adv Prostaglandin Thromboxane Leukot Res. 1994;22:217–226. [PubMed]
  • Drazen JM, Lilly CM, Sperling R, Rubin P, Israel E. Role of cysteinyl leukotrienes in spontaneous asthmatic responses. Adv Prostaglandin Thromboxane Leukot Res. 1994;22:251–262. [PubMed]
  • Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol. 1938 Nov 14;94(2):187–226. [PubMed]
  • BROCKLEHURST WE. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol. 1960 Jun;151:416–435. [PubMed]
  • Murphy RC, Hammarström S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4275–4279. [PubMed]
  • Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990 Jan 18;343(6255):282–284. [PubMed]
  • Hatzelmann A, Goossens J, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. Biochem Pharmacol. 1994 Jun 15;47(12):2259–2268. [PubMed]
  • Orning L, Kaijser L, Hammarström S. In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4. Biochem Biophys Res Commun. 1985 Jul 16;130(1):214–220. [PubMed]
  • Owen WF, Jr, Soberman RJ, Yoshimoto T, Sheffer AL, Lewis RA, Austen KF. Synthesis and release of leukotriene C4 by human eosinophils. J Immunol. 1987 Jan 15;138(2):532–538. [PubMed]
  • Fox CC, Kagey-Sobotka A, Schleimer RP, Peters SP, MacGlashan DW, Jr, Lichtenstein LM. Mediator release from human basophils and mast cells from lung and intestinal mucosa. Int Arch Allergy Appl Immunol. 1985;77(1-2):130–136. [PubMed]
  • Schleimer RP, Schulman ES, MacGlashan DW, Jr, Peters SP, Hayes EC, Adams GK, 3rd, Lichtenstein LM, Adkinson NF., Jr Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest. 1983 Jun;71(6):1830–1835. [PMC free article] [PubMed]
  • Dahlén SE, Dahlén B, Kumlin M, Björck T, Ihre E, Zetterström O. Clinical and experimental studies of leukotrienes as mediators of airway obstruction in humans. Adv Prostaglandin Thromboxane Leukot Res. 1994;22:155–166. [PubMed]
  • Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. [PubMed]
  • Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984 Jul;39(7):500–504. [PMC free article] [PubMed]
  • Griffin M, Weiss JW, Leitch AG, McFadden ER, Jr, Corey EJ, Austen KF, Drazen JM. Effects of leukotriene D on the airways in asthma. N Engl J Med. 1983 Feb 24;308(8):436–439. [PubMed]
  • Davidson AB, Lee TH, Scanlon PD, Solway J, McFadden ER, Jr, Ingram RH, Jr, Corey EJ, Austen KF, Drazen JM. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis. 1987 Feb;135(2):333–337. [PubMed]
  • Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982 Sep;126(3):449–451. [PubMed]
  • Peck MJ, Piper PJ, Williams TJ. The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin. Prostaglandins. 1981 Feb;21(2):315–321. [PubMed]
  • Arm JP, Spur BW, Lee TH. The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol. 1988 Oct;82(4):654–660. [PubMed]
  • Bel EH, van der Veen H, Kramps JA, Dijkman JH, Sterk PJ. Maximal airway narrowing to inhaled leukotriene D4 in normal subjects. Comparison and interaction with methacholine. Am Rev Respir Dis. 1987 Oct;136(4):979–984. [PubMed]
  • Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993 Apr 17;341(8851):989–990. [PubMed]
  • Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 1990 Jul;142(1):112–119. [PubMed]
  • Taylor GW, Taylor I, Black P, Maltby NH, Turner N, Fuller RW, Dollery CT. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. [PubMed]
  • Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989 Jul;84(1):19–26. [PubMed]
  • Okubo T, Takahashi H, Sumitomo M, Shindoh K, Suzuki S. Plasma levels of leukotrienes C4 and D4 during wheezing attack in asthmatic patients. Int Arch Allergy Appl Immunol. 1987;84(2):149–155. [PubMed]
  • Barnes N, Piper PJ, Costello J. The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol. 1987 May;79(5):816–821. [PubMed]
  • Evans JM, Barnes NC, Zakrzewski JT, Sciberras DG, Stahl EG, Piper PJ, Costello JF. L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man. Br J Clin Pharmacol. 1989 Aug;28(2):125–135. [PMC free article] [PubMed]
  • Phillips GD, Rafferty P, Robinson C, Holgate ST. Dose-related antagonism of leukotriene D4-induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects. J Pharmacol Exp Ther. 1988 Aug;246(2):732–738. [PubMed]
  • Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):988–992. [PubMed]
  • Kips JC, Joos GF, De Lepeleire I, Margolskee DJ, Buntinx A, Pauwels RA, Van der Straeten ME. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):617–621. [PubMed]
  • Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med. 1993 Feb;87(2):133–138. [PubMed]
  • Evans JM, Piper PJ, Costello JF. The pharmacological profile of SK&F 104353-Z2, a potent, selective inhaled antagonist of cysteinyl leukotrienes, in normal man. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:469–472. [PubMed]
  • Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, Drazen JM. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990 Dec 20;323(25):1740–1744. [PubMed]
  • Friedman BS, Bel EH, Buntinx A, Tanaka W, Han YH, Shingo S, Spector R, Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993 Apr;147(4):839–844. [PubMed]
  • Zakrzewski JT, Barnes NC, Costello JF, Piper PJ. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987 Sep;136(3):779–782. [PubMed]
  • Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. [PubMed]
  • Rasmussen JB, Margolskee DJ, Eriksson LO, Williams VC, Andersson KE. Leukotriene (LT) D4 is involved in antigen-induced asthma: a study with the LTD4 receptor antagonist, MK-571. Ann N Y Acad Sci. 1991;629:436–436. [PubMed]
  • Aalbers R, de Monchy JG. Cysteinyl-leukotriene receptor antagonist, bronchoconstriction, and airway hyperreactivity. Lancet. 1991 Aug 17;338(8764):445–445. [PubMed]
  • Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990 Dec 20;323(25):1736–1739. [PubMed]
  • Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746–749. [PubMed]
  • Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991 May 4;337(8749):1062–1063. [PubMed]
  • Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992 Aug;146(2):358–363. [PubMed]
  • Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993 Dec 1;119(11):1059–1066. [PubMed]
  • Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991 May;143(5 Pt 1):1025–1029. [PubMed]
  • Dahlén B, Margolskee DJ, Zetterström O, Dahlén SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax. 1993 Dec;48(12):1205–1210. [PMC free article] [PubMed]
  • Dahlén B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, Zetterström O, Dahlén SE. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1993 Jul;6(7):1018–1026. [PubMed]
  • Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994 Sep;150(3):618–623. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press